AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX

ARX - AROA BIOSURGERY LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 6.8
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.65

18 Nov
2025

-0.035

OPEN

$0.75

-5.11%

HIGH

$0.75

257,214

LOW

$0.64

TARGET
$0.825 26.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 0.8 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 85.7 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx77.1 M
Book Value Per Share xxxxxxxxxxxxxxx24.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-2.3 M
Net Profit Margin xxxxxxxxxxxxxxx-4.50 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-4.04 %
Return on Invested Capital xxxxxxxxxxxxxxx-3.81 %
Return on Assets xxxxxxxxxxxxxxx-3.46 %
Return on Equity xxxxxxxxxxxxxxx-4.04 %
Return on Total Capital xxxxxxxxxxxxxxx-3.96 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-4.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx5 M
Total Debt xxxxxxxxxxxxxxx6 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx20 M
Price To Book Value xxxxxxxxxxxxxxx1.73

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx3.4 M
Capex % of Sales xxxxxxxxxxxxxxx4.37 %
Cost of Goods Sold xxxxxxxxxxxxxxx11 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx70 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

17/10/2025

2

Downgrade to Accumulate from Speculative Buy

$0.80

23.08%

Morgans points to a "solid" 2Q26 cash flow report for Aroa Biosurgery, which equates to a fourth consecutive quarter of positive operating cash flow. FY26 guidance was reiterated, a further positive, in the analyst's view.

The stock is downgraded to Accumulate from Speculative Buy with a lift in target to 80c from 77c. There are no changes to the analyst's earnings forecasts.

The biotech is due to report 1H26 results on November 25, with a randomised control trial for Symphony anticipated to conclude in November for peer review.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.09 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.26 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

28/10/2025

1

Buy

$0.90

38.46%

Canaccord Genuity notes Aroa Biosurgery's 2Q26 result was in line with expectations, highlighted by record Myriad sales of NZ$10.2m (up 30% y/y).

FY26 guidance was maintained, but the broker sees upside risks if an IDN win materialises earlier than expected. TELA Bio remains in a “show me” phase, but salesforce and strategy improvements support the broker's optimism.

Operating leverage is seen strengthening in FY26-27, with only 15% revenue growth needed to double EBITDA.

Buy. Target unchanged at 90c.
Access Extra Coverage Research History >

ARX STOCK CHART

FNArena News on ARX

1
Australian Broker Call *Extra* Edition – Oct 28, 2025

Oct 28 2025 - Daily Market Reports
2
Weekly Ratings, Targets, Forecast Changes – 17-10-25

Oct 20 2025 - Weekly Reports
3
In Brief: NRW Holdings, Aroa Biosurgery, Online Retail Winners

Sep 12 2025 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Aug 18, 2025 (Extra)

Aug 18 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 14, 2025

Aug 14 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
2
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
3
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
4
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
5
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
6
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
7
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
8
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
9
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
10
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia